Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers

Bone Marrow Transplantation

Volumn 19, Issue 7, 1997, Pages 671-678

  Weaver, C H ^a   Schwartzberg, L S ^a   Hainsworth, J ^b   Greco, F A ^b   Li, W ^a   Buckner, C D ^a,c   West, W H ^a  

^a Response Oncology Inc   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c Responce Oncology Inc   (United States)

Author keywords

Treatment related mortality

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; THIOTEPA;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BREAST CANCER; CANCER; CANCER CENTER; CAUSE OF DEATH; CLINICAL TRIAL; COMMUNITY CARE; DISEASE COURSE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HODGKIN DISEASE; HUMAN; HUMAN CELL; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LEUKOCYTE COUNT; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAFETY; SARCOMA; STEM CELL TRANSPLANTATION;

EID: 0030934506     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700713     Document Type: Article

References (45)

1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
2. Linch DC, Hancock B, Winfield D et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
3. Cunningham D, Paz-Ares L, Milan S et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-763.
4. Cunningham D, Paz-Ares L, Gore ME et al. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol 1994; 12: 764-768.
5. Attal M, Harousseau JL, Stoppa AM et al. High dose therapy in multiple myeloma: final analysis of a prospective randomized study of the Intergroupe Français du Myelome (IFM 90). Proc Am Soc Hematol 1995: 86:124a (Abstr.).
6. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
7. Peters WP, Jones RB, Vredenburgh J et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). San Antonio Breast Cancer Symposium 1995, p 35 (Abstr.).
8. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
9. Stiff PJ, McKenzie RS, Alberts DS et al. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. J Clin Oncol 1994; 12: 176-183.
10. Weaver CH, Schwartzberg LS, Li W et al. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease. Bone Marrow Transplant 1996; 17: 715-721.
11. Schwartzberg L, Birch R, Hazelton B et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1: 317-327.
12. Schwartzberg L, Birch R, Blanco R et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993; 11: 369-374.
13. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
14. Schiffman KS, Bensinger WI, Appelbaum FR et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996; 17: 943-950.
15. Philip T, Chauvin F, Armitage JO. PARMA International Protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991; 17: 1587-1592.
16. Weaver CH, Bensinger WJ, Appelbaum K et al. Phase I study of high-dose busulfan, melphalan, thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813-819.
17. Tutschka PJ, Copeland EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
18. Shuhart MC, McDonald GB. Gastrointestinal and hepatic complications. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific: Boston, 1994, pp 454-481.
19. Crawford SW. Critical care and respiratory failure. In: Thomas ED, Forman SJ, Blume K (eds). Bone Marrow Transplantation. Blackwell Scientific: Boston, 1994, pp 513-526.
20. Bowden RA, Slichter SJ, Sayers M et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598-3603.
21. Schwartz C, Henrickson K, Roghmann K, Powell K. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol 1990; 8: 1591-1597.
22. Weaver CH, Appelbaum FR, Petersen FB et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J clin Oncol 1993; 11: 1329-1335.
23. Philip T, Dumont J, Teillet F. High-dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease. Br J Cancer 1986; 53: 737-742.
24. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
25. Appelbaum FR, Sullivan KM, Buckner CD. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5: 1340-1347.
26. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81: 1137-1145.
27. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990; 17: 10-13.
28. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326: 845-851.
29. Wingard JR, Merz WG, Rinaldi MG et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New Engl J Med 1991; 325: 1274-1277.
30. Walsh TJ, Pizzo PA. Fungal infections in granulocytopenic patients: current approaches to classification, diagnosis, and treatment. In: Holmberg K, Meyer R (eds). Diagnosis and Therapy of Systemic Fungal Infections. Raven Press: New York, 1989, pp 47-70.
31. Boeckh M, Gooley T, Reusser P et al. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 1995; 172: 939-943.
32. Quan CM, Bowden RA. Clinical aspects of cytomegalovirus infection in marrow transplantation. Marrow Transplant Rev 1993; 3: 17-21.
33. Reusser P, Fisher LD, Buckner CD et al. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 1990; 75: 1888-1894.
34. Miller WJ, McCullough J, Balfour HH et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991; 7: 227-234.
35. Verdonck LF, deGraan-Hentzen YC, Dekker AW et al. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant 1987; 2: 73-78.
36. Bowden RA, Slichter SJ, Sayers MH et al. Use of leukocytedepleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246-250.
37. Wheeler C, Antin JH, Churchill WH. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8: 648-656.
38. Reece DE, Barnett MJ, Connors JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's Disease. J Clin Oncol 1991; 9: 1871-1879.
39. McDonald G, Sharma P, Matthews D et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 4: 116-122.
40. Eder JP, Elias A, Shea TC et al. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990; 8: 1239-1245.
41. Barlogie B, Alexanian R, Dicke K et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869-872.
42. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBPCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
43. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
44. Nemunaitis J, Rabinowe WN, Singer JW et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New Engl J Med 1991; 324: 1773-1778.
45. Rabinowe SN, Neuberg D, Bierman PJ et al. Long term follow-up of a phase III study of rhGM-CSF after autologous bone marrow transplantation for lymphoid malignancies. Blood 1993; 81: 1903-1908.